Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2011

01-07-2011 | Original Article

Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer

Authors: Chiun-Wei Huang, Zibo Li, Hancheng Cai, Kai Chen, Tony Shahinian, Peter S Conti

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2011

Login to get access

Abstract

Purpose

The ability of PET to aid in the diagnosis and management of recurrent and/or disseminated metastatic prostate cancer may be enhanced by the development of novel prognostic imaging probes. Accumulating experimental evidence indicates that overexpression of integrin α2β1 may correlate with progression in human prostate cancer. In this study, 64Cu-labeled integrin α2β1-targeted PET probes were designed and evaluated for the imaging of prostate cancer.

Methods

DGEA peptides conjugated with a bifunctional chelator (BFC) were developed to image integrin α2β1 expression with PET in a subcutaneous PC-3 xenograft model. The microPET images were reconstructed by a two-dimensional ordered subsets expectation maximum algorithm. The average radioactivity accumulation within a tumor or an organ was quantified from the multiple region of interest volumes.

Results

The PET tracer demonstrated prominent tumor uptake in the PC-3 xenograft (integrin α2β1-positive). The receptor specificity was confirmed in a blocking experiment. Moreover, the low tracer uptake in a CWR-22 tumor model (negative control) further confirmed the receptor specificity.

Conclusion

The sarcophagine-conjugated DGEA peptide allows noninvasive imaging of tumor-associated α2β1 expression, which may be a useful PET probe for evaluating the metastatic potential of prostate cancer.
Literature
1.
2.
Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907–23.PubMed
3.
Kotzerke J, Gschwend JE, Neumaier B. PET for prostate cancer imaging: still a quandary or the ultimate solution? J Nucl Med. 2002;43:200–2.PubMed
4.
Lafrenie RM, Buckner CA, Bewick MA. Cell adhesion and cancer: is there a potential for therapeutic intervention? Expert Opin Ther Targets. 2007;11:727–31.PubMedCrossRef
5.
Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis. 2003;20:203–13.PubMedCrossRef
6.
Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM. Integrins and cancer. Oncology (Williston Park). 2007;21:13–20.
7.
Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90:561–5.PubMedCrossRef
8.
Stupack DG. The biology of integrins. Oncology (Williston Park). 2007;21:6–12.
9.
Kostenuik PJ, Sanchez-Sweatman O, Orr FW, Singh G. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis. 1996;14:19–26.PubMedCrossRef
10.
Lang SH, Clarke NW, George NJ, Testa NG. Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. Clin Exp Metastasis. 1997;15:218–27.PubMedCrossRef
11.
Hall CL, Dai J, van Golen KL, Keller ET, Long MW. Type I collagen receptor (α2β1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res. 2006;66:8648–54.PubMedCrossRef
12.
Kiefer JA, Farach-Carson MC. Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: implications for enhanced growth in the bone microenvironment. Matrix Biol. 2001;20:429–37.PubMedCrossRef
13.
Tantivejkul K, Kalikin LM, Pienta KJ. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem. 2004;91:706–17.PubMedCrossRef
14.
Slack-Davis JK, Parsons JT. Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem. 2004;91:41–6.PubMedCrossRef
15.
Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005;173:10–20.PubMedCrossRef
16.
Huang CW, Li Z, Cai HC, Shahinian AH, Conti PS. Novel α2β1 integrin-targeted peptide probes for prostate cancer imaging. Mol Imaging. doi:MI_​2010_​00044.​3d.
17.
Hancock WS, Battersby JE. A new micro-test for the detection of incomplete coupling reactions in solid-phase peptide synthesis using 2,4,6-trinitrobenzenesulphonic acid. Anal Biochem. 1976;71:260–4.PubMedCrossRef
18.
Li Z, Wu Z, Chen K, Ryu EK, Chen X. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med. 2008;49:453–61.PubMedCrossRef
19.
Liu Z, Li Z, Cao Q, Liu S, Wang F, Chen X. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med. 2009;50:1168–77.PubMedCrossRef
20.
Giancotti FG, Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol. 2003;19:173–206.PubMedCrossRef
21.
Cai H, Fissekis J, Conti PS. Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and (64)Cu radiolabelling. Dalton Trans. 2009;27:5395–400.PubMedCrossRef
22.
Cai H, Li Z, Huang C, Park R, Shahinian AH, Conti PS. An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals. Nucl Med Biol. 2010;37:57–65.PubMedCrossRef
23.
Cai H, Li Z, Huang C, Shahinian AH, Wang H, Park R, et al. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alpha(v)beta(3) expression. Bioconjug Chem. 2010;21:1417–24.PubMedCrossRef
24.
Sancey L, Garanger E, Foillard S, Schoehn G, Hurbin A, Albiges-Rizo C, et al. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol Ther. 2009;17:837–43.PubMedCrossRef
Metadata
Title
Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer
Authors
Chiun-Wei Huang
Zibo Li
Hancheng Cai
Kai Chen
Tony Shahinian
Peter S Conti
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1752-x

Other articles of this Issue 7/2011

European Journal of Nuclear Medicine and Molecular Imaging 7/2011 Go to the issue

Review Article

Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting

Original Article

[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression

Letter to the Editor

Focus on…: Čerenkov radiation

Original Article

Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer

Book Review

Brian J. McParland: Nuclear medicine radiation dosimetry. Advanced theoretical principles

Original Article

Viability and proliferation potential of adipose-derived stem cells following labeling with a positron-emitting radiotracer